News | Prostate Cancer | October 28, 2015

Augmenix Highlights Rapid U.S. Adoption of SpaceOAR System at ASTRO 2015

Series of presentations demonstrate hydrogel spacer’s ability to reduce radiation dose to rectum during prostate cancer treatment

SpaceOAR System, rapid U.S. adoption, prostate cancer radiotherapy, ASTRO 2015

Image courtesy of Augmenix Inc.

October 28, 2015 — Augmenix Inc. showcased the SpaceOAR System at the 57th annual American Society of Therapeutic Radiology and Oncology (ASTRO) meeting, highlighting robust commercial uptake in the United States. An absorbable hydrogel, SpaceOAR technology is designed to create space and protect the rectum in men undergoing prostate cancer radiotherapy. The device received clearance from the U.S. Food and Drug Administration (FDA) in April 2015 and since then, more than 40 cancer treatment centers in 19 states have adopted it.

“For decades, attempts to limit rectum radiation injury in men receiving prostate cancer radiotherapy included advances in planning and delivery, along with improvements in prostate localization and enhanced image guidance. As we observe increasing interest worldwide in high-dose, ultra-hypofractionated treatment delivery regimens, the rectal tolerance to these high radiation dose levels represents a significant clinical concern,” said Michael J. Zelefsky, M.D., Memorial Sloan Kettering Cancer Center. “The concept of an absorbable hydrogel implant pushing the rectum away from the prostate is a totally new approach and a potential game changer. The use of SpaceOAR for this clinical setting may reduce long-term rectal toxicity and become a critical adjunct to the safe implementation of high-dose SBRT [stereotactic body radiation therapy].”

Despite advancements in prostate cancer radiotherapy, the close proximity of the prostate to the rectum (defined as the organ at risk, or OAR) limits the total amount of radiation that can be delivered safely to the prostate without fear of rectum radiation injury. In fact, in 1996 and 2003, the published median volume of rectum receiving 70Gy radiation (or V70, a predictor of long-term rectal complications) was 21.7 percent and 18.2 percent, respectively (RTOG 9406 and 0126 studies). In comparison, the median rectum V70 radiation in the recently published SpaceOAR study was 2.3 percent.

The low rectal radiation doses made possible by the SpaceOAR System will enable advanced prostate cancer radiation protocols that should result in fewer rectal complications (including rectal pain during treatment and declines in bowel quality of life), higher prostate radiation doses and faster treatment times, translating into better patient outcomes, reduced cancer recurrence and healthcare savings. These benefits are helping to drive rapid adoption of the technology for use in SBRT, intensity modulated radiation therapy (IMRT), low-dose rate brachytherapy (LDR), high-dose rate brachytherapy (HDR) and proton radiotherapy procedures.

The SpaceOAR System was the subject of several symposium presentations at ASTRO 2015, including:

  • John Sylvester, M.D., radiation oncologist at 21st Century Oncology, presented the SpaceOAR U.S. Pivotal study results;
  • Marcio Fagundes, M.D., medical director at Provision Center for Proton Therapy, discussed spacer use in proton radiotherapy; and
  • Robert Timmerman, M.D., professor and vice chair of the Department of Radiation Oncology and professor of neurosurgery at UT Southwestern, discussed spacer use in dose-escalated SBRT. 

Using a minimally invasive procedure, the SpaceOAR System is injected as a liquid into the space between the prostate and rectum where it expands the space and then solidifies into a soft hydrogel. The hydrogel remains stable for three months while protecting the rectum during radiotherapy and then liquefies and is completely absorbed.

The SpaceOAR System is FDA-cleared, CE marked and TGA-approved.

For more information: www.augmenix.com

Related Content

Videos | Radiation Therapy | August 13, 2018
ITN Editor Dave Fornell takes a tour of some of the innovative new technologies on the expo floor at the 2018 America
Videos | Radiation Therapy | August 13, 2018
A discussion with Mahadevappa Mahesh, MS, Ph.D., FAAPM, FACR, FACMP, FSCCT, professor of radiology and cardiology and
Videos | Proton Therapy | August 10, 2018
A discussion with Matthew Freeman, Ph.D., scientist at Los Alamos National Laboratory, New Mexico.
Exact Imaging Becomes UroGPO Imaging Partner
News | Ultrasound Imaging | August 10, 2018
Exact Imaging announced that it has become a UroGPO Imaging Partner, joining the North American urology-specific group...
Videos | Radiomics | August 09, 2018
A discussion with Martin Vallieres, Ph.D., post-doctoral fellow at McGill University, Montreal, Canada.
Videos | AAPM | August 03, 2018
Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke Un...
Videos | Radiation Therapy | August 01, 2018
This is an example of how Cherenkov radiation glow can be collected with image intensifier cameras during radiotherap
Videos | Artificial Intelligence | August 01, 2018
A discussion with Steve Jiang, Ph.D., director of the medical...
Videos | AAPM | August 01, 2018
American Association of Physicists in Medicine (AAPM) President Bruce Thomadsen, M.D., professor of medical physics a
IBA Completes Installation of Two Proteus One Proton Therapy Systems in Japan
News | Proton Therapy | July 30, 2018
IBA (Ion Beam Applications S.A.) announced that they completed the first two installations of the Proteus One proton...
Overlay Init